Mike has more than 25 years of pharmaceutical development experience and has focused on clinical-stage product companies, particularly in the oncology and neurology areas. He is currently Executive Partner at Omega Funds and was Managing General Partner at Sofinnova Investments from 1997-2021. Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including an 1,000–page treatise on vaccine design. Mike was the initial investor in a number of companies that went public, including: Actelion (SWX: ATLN), InterMune (Nasdaq: ITMN), Orexigen Therapeutics (Nasdaq: OREX), Seattle Genetics (Nasdaq: SGEN), Threshold Pharmaceuticals (Nasdaq: THLD) and Trius Therapeutics (Nasdaq: TSRX), as well as several private companies, including Intellikine (acquired by Millennium/Takeda), Labrys Biologics (acquired by Teva) and Pionyr Therapeutics (partnered with Gilead). Mike is currently Board Chair of Galera Therapeutics (Nasdaq: GRTX), and on the Board of Trustees of Washington University in St. Louis. He is past Board President of AVAC (AIDS Vaccine Advocacy Coalition) in NYC, a former Advisor to the Bill and Melinda Gates Foundation, a former Strategic Advisor to One World Health and a Founding Venture Advisory Board member of the IAVI (International AIDS Vaccine Initiative) Innovation Fund. He is an Adjunct Professor in Pharmaceutical Chemistry at the University of Kansas and served on the advisory board of the Institute for the Advancement of Medical Innovation at the University of Kansas. Mike had senior level operation roles at Genentech, Cytel, and Syntex Research and was the first scientist from the biotechnology industry to be elected a Fellow of the American Association of Pharmaceutical Scientists. He received his PhD in Physical Chemistry from the University of Toronto, and a postdoc at the University of California, where he was a faculty member before moving into biotech.
Peter is Principal at Decheng Capital, which he joined in October 2016. In addition this expertise in finance, investment, transaction, operational and drug development, he brings a passion to find a cure for cancer and bring life-saving drugs to patients. Prior to joining Decheng, Peter held positions in business and corporate development, sales and marketing, and company startups. As Associate at Frazier Healthcare Ventures, he led the investment and company formation for Silvergate Pharmaceuticals, a pediatric rare disease company that to date has launched four internally developed and proprietary products, and served as Vice President of Business Development & Managed Care at the company. At Frazier, he was involved in and served as board observer for Calistoga Pharmaceuticals, VentiRx, Alnara Pharma, and Oceana Therapeutics, as well as several of the firm’s public investments. Prior to Frazier, he served in the Morgan Stanley and Cowen Healthcare Investment Banking groups. Mr. Colabuono holds a B.A. in Molecular Biology and Biochemistry from Dartmouth College, is an inventor and author on issued patents and journal articles, and is active with the Head & Neck Cancer Alliance.
Mr. Fuhrman is an experienced financial operations leader with a focus on guiding the growth of innovative pharmaceutical and biotechnology companies. Alan is a member of the Board of Directors for SpringWorks Therapeutics and Esperion Therapeutics. Alan also served on the Board of Directors and as Chair of the Audit Committee for Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019. He previously served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020. Prior to joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company that merged with Synlogic in August 2017. Alan previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Earlier in his career, Alan practiced as a certified public accountant with Coopers & Lybrand. Alan received a B.S. in both Business Administration and Agricultural Economics from Montana State University.
Jon Wigginton, MD
Dr. Wigginton has over 25 years of experience in clinical oncology and currently serves as Senior Advisor and Chairman of the SAB at Cullinan Oncology, Inc. as well as a member of the Board of Directors of Sutro Biopharma. He previously served as Chief Medical Officer at Cullinan Oncology, Inc., and an advisor for MPM Capital. Prior, he was Chief Medical Officer at MacroGenics, where he led the company’s evolution of a fully-integrated clinical-stage cancer immunotherapy organization. Dr. Wigginton also served as Therapeutic Area Head in Immuno-Oncology for Early Clinical Research at Bristol Myers Squibb. Prior to that, Dr. Wigginton was Director, Clinical Oncology at Merck Research Laboratories. In addition, he previously served as President of the Society for Immunotherapy of Cancer (SITC). Earlier in his career, Dr. Wigginton worked at the NCI for over 14 years and was Head of the Investigational Biologics Section in the Center for Cancer Research (intramural program). He earned his MD and BS in biology from the University of Michigan.
CEO & PresidentRead More
Mr. Bash has 23 years of strategic and operational leadership experience, managing businesses, building teams and launching products that have helped improve patients’ lives across a number of therapeutic areas. He joins Checkmate from Bristol Myers Squibb (BMS), where he most recently served as Senior Vice President, Commercial Model Innovation, and prior to that, Senior Vice President, Commercial for Immunology and Fibrosis, partnering with Research & Development to advance early and late-stage assets in the integrated BMS and Celgene portfolios. Mr. Bash has a deep expertise in immuno-oncology, having led the U.S. launch of the PD-1 checkpoint inhibitor, Opdivo; serving as franchise lead for metastatic melanoma; and leading the launch of the first FDA-approved checkpoint combination. He also served as Worldwide Vice President for BMS’s lung cancer franchise and led the product team for a targeted treatment for head and neck cancer and colorectal cancer. During his tenure at BMS, he was a champion for talent development, served as co-chair of the diversity and inclusion council, and was the executive sponsor for Women in Immunology. Mr. Bash earned his BA from Georgetown University and his MBA from Columbia Business School.
Keith Flaherty, MD
Dr. Flaherty is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, Director of Clinical Research, Massachusetts General Hospital Cancer Center and Editor-in-Chief of Clinical Cancer Research. He co-founded and served on the Board of Directors of Loxo Oncology, Inc. until its acquisition by Eli Lilly and Company and he currently serves on the Board of Directors of Clovis Oncology, Inc. (NASDAQ: CLVS). Dr. Flaherty has a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.
Oren K. Isacoff, MD
Dr. Isacoff is the Chief Development Officer at Curalta Health. Dr. Isacoff previously served as a Principal at Longitude Capital from 2015 to 2021. Prior to joining Longitude Capital, Dr. Isacoff was a Senior Associate on the Healthcare Team of TPG Special Situations Partners. Dr. Isacoff completed his internship at Massachusetts General Hospital and maintains an active medical license. Dr. Isacoff is a board observer at Inozyme, KaNDy Therapeutics and Velicept Therapeutics, and has been actively involved with Longitude Capital’s investments in Cydan Development, Poseida Therapeutics and Tricida (TCDA). He previously served as a board observer at Inozyme (INZY), KaNDy Therapeutics (acquired by Bayer) and Zavante Therapeutics (acquired by Nabriva). Dr. Isacoff holds an MD and an MBE from the Perelman School of Medicine, an MBA from the Wharton School, and a BA in Political Science and a BS in Economics from the University of Pennsylvania.
Joy Yan, MD, PhD
Dr. Yan is the Chief Medical Officer of KeyMed Biosciences and an independent Board Member of Moleculin Biotech, Inc. She also serves on the Scientific Advisory Board of Ambrx Biopharma Inc. Previously, she served as Chief Medical Officer at Ambrx, where she led the pipeline strategy and quickly advanced three antibody drug conjugate (ADC) development programs. She also led the cross-over financing and IPO of Ambrx. Previously at Bristol Myers Squibb, she led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS’ first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. She also has broad clinical development experience at Janssen and Bayer, where she led Phase I, II and III studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, Bi-specifics, ADCs, TKIs) across multiple tumor types. Dr. Yan completed her PhD in Biochemistry & Molecular Biology at Johns Hopkins University. She received her MD from China Medical University and completed her residency and clinical fellowship at University of Washington.